Results 151 to 160 of about 636,170 (221)

BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. [PDF]

J Clin Exp Hematop
Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S.   +4 more
europepmc   +1 more source

Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors. [PDF]

Ann Hematol
Garcia M, Croizier C, Lazarian G, Quinquenel A, Tassin T, Bourgne C, Tournilhac O, Bay JO, Berger MG, Tchirkov A, Véronèse L, Guièze R.   +11 more
europepmc   +1 more source

High rate of complete responses induced by platinum-based regimen with BTK inhibitors in Richter syndrome. [PDF]

Blood Adv
Pongas G, Alasfour M, Cassidy DP, Alderuccio JP, Rosenblatt JD, Lossos IS.   +5 more
europepmc   +1 more source

"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors. [PDF]

Haematologica
Grainger BT, Cheah CY.
europepmc   +1 more source

Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma. [PDF]

Cancer Immunol Immunother
Yu L, Ping N, Zou R, Zhu Q, Li J, Zhang X, Xia F, He J, Tu J, Kong D, Wu D, Jin Z, Qu C.   +12 more
europepmc   +1 more source

Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy. [PDF]

Ther Adv Neurol Disord
Shirani A, Saez-Calveras N, Antel JP, Yaqubi M, Moore W, Brewster AL, Stuve O.   +6 more
europepmc   +1 more source

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma. [PDF]

Ann Hematol
Yang P, Li CY, Liu SZ, Wang J, Chen YT, Zhang WL, Jing HM.   +6 more
europepmc   +1 more source

Real-world use of BTK inhibitors for chronic lymphocytic leukemia in Japan: A retrospective observational database study. [PDF]

J Clin Exp Hematop
Nishikori M, Nozaki K, Hayashi Y, Arita Y, Fujiwara M, Iwao C, Kitagawa H, Maruyama D.   +7 more
europepmc   +1 more source

BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study. [PDF]

Am J Hematol
Roeker LE, Han Y, Teschemaker A, Mato AR, Thompson MC.   +4 more
europepmc   +1 more source